Trial Condition(s):
Atrial Fibrillation
Registry study of adherence to treatment with rivaroxaban and warfarin in patients with atrial fibrillation, as requested by the Dental and Pharmaceutical Benefits Board (TLV)
Bayer Identifier:
18491
ClinicalTrials.gov Identifier:
Not Available
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
This is a retrospective registry study to describe and compare the adherence among AF patients initiating treatment with rivaroxaban (without previous warfarin or NOAC use) with those initiating treatment with warfarin (with and without previous warfarin or NOAC use). It is a requirement by The Dental and Pharmaceutical Benefits Board (TLV) in Sweden to provide data on a comparison of adherence to NOAC treatment vs. warfarin for newly treated patients in atrial fibrillation. Several Swedish registries will be utilized.
Inclusion Criteria
No Inclusion Criteria Available
Exclusion Criteria
No Exclusion Criteria Available
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | |
|---|---|
Locations Investigative Site Many locations, Sweden | Contact Us: E-mail: [email protected] Phone: Not Available |
For details, please refer to trial results
Additional Information
Copyright © Bayer
Powered by
